Redox-responsive Metal-organic Framework Nanocapsules Enhance Tumor Chemo-immunotherapy by Modulating Tumor Metabolic Reprogramming

Overview

Journal Mater Today Bio

Date 2025 Feb 3

PMID 39896279

Authors

Yuman Dong

Jieru Li

Yiwei Dai

Xinyu Zhang

Tao Wang

Bin Zhao

Wenbo Liu

Li Chen

Shaopei Yang

Pengcheng Du

Zuoyi Jiao

Affiliations

Soon will be listed here.

Abstract

Immunotherapy, particularly immune checkpoint blockade (ICB), has opened the era of modern oncology, offering significant promise for modern oncology. However, the efficacy of immunotherapy is frequently curtailed by the immunosuppressive tumor microenvironment (ITM), a milieu shaped by tumor metabolic reprogramming. Herein, a novel tumor microenvironment-responsive nanocapsules (DNMCs) were developed that simultaneously modulate tumor metabolism and the ITM to enhance the effectiveness of chemo-immunotherapy. DNMCs consist of an acidic and redox-sensitive metal-organic framework (MOF) encapsulating Doxorubicin (DOX) and the indoleamine-2,3-dioxygenase1 (IDO1) inhibitor NLG919. In the tumor microenvironment, DNMCs degrade, rapidly releasing DOX and NLG919. DOX induces immunogenic cell death (ICD), while NLG919 regulates amino acid metabolism by modulating IDO1 activity, thereby reversing the immunosuppressive of ITM. Consequently, DNMCs elicit effective anti-tumor immune responses, characterized by an increased density of tumor-infiltrating CD8 cytotoxic T cells as well as depletion of immunosuppressive regulatory T cells (Tregs), thus effectively suppressing pancreatic cancer growth in KPC mice through combined chemo-immunotherapy. Overall, DNMCs exhibit significant tumor growth inhibition in pancreatic cancer patient-derived organoids (PDOs) and mouse models. This study presents a promising approach to enhancing chemo-immunotherapy by targeting tumor metabolic reprogramming and augmenting immune response against malignant tumors.

References

Zhai L, Bell A, Ladomersky E, Lauing K, Bollu L, Nguyen B . Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021; 27(23):6514-6528. PMC: 8639612. DOI: 10.1158/1078-0432.CCR-21-1392. View

Guo X, Cheng Y, Zhao X, Luo Y, Chen J, Yuan W . Advances in redox-responsive drug delivery systems of tumor microenvironment. J Nanobiotechnology. 2018; 16(1):74. PMC: 6151045. DOI: 10.1186/s12951-018-0398-2. View

Feng B, Zhou F, Hou B, Wang D, Wang T, Fu Y . Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment. Adv Mater. 2018; 30(38):e1803001. DOI: 10.1002/adma.201803001. View

Ding N, He K, Tian H, Li L, Li Q, Lu S . Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis. Mater Today Bio. 2023; 20:100645. PMC: 10189275. DOI: 10.1016/j.mtbio.2023.100645. View

Yang S, Shim M, Kim W, Choi J, Nam G, Kim J . Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials. 2021; 272:120791. DOI: 10.1016/j.biomaterials.2021.120791. View

Fujiwara Y, Kato S, Nesline M, Conroy J, DePietro P, Pabla S . Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022; 110:102461. DOI: 10.1016/j.ctrv.2022.102461. View

Liu D, Liang C, Huang B, Zhuang X, Cui W, Yang L . Tryptophan Metabolism Acts as a New Anti-Ferroptotic Pathway to Mediate Tumor Growth. Adv Sci (Weinh). 2023; 10(6):e2204006. PMC: 9951368. DOI: 10.1002/advs.202204006. View

Ho W, Jaffee E, Zheng L . The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020; 17(9):527-540. PMC: 7442729. DOI: 10.1038/s41571-020-0363-5. View

Li Y, Wu Y, Fang Z, Zhang Y, Ding H, Ren L . Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo-Immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment. Adv Mater. 2023; 36(2):e2307263. DOI: 10.1002/adma.202307263. View

10.

Seo S, Kwon B . Immune regulation through tryptophan metabolism. Exp Mol Med. 2023; 55(7):1371-1379. PMC: 10394086. DOI: 10.1038/s12276-023-01028-7. View

11.

Lotze M, Zeh H, Rubartelli A, Sparvero L, Amoscato A, Washburn N . The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007; 220:60-81. DOI: 10.1111/j.1600-065X.2007.00579.x. View

12.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K . Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359(6378):920-926. PMC: 6112415. DOI: 10.1126/science.aao2774. View

13.

Platt C, Ma J, Chalouni C, Ebersold M, Bou-Reslan H, Carano R . Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci U S A. 2010; 107(9):4287-92. PMC: 2840134. DOI: 10.1073/pnas.0910609107. View

14.

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

15.

Zhang Z, Pan Z, Li Q, Huang Q, Shi L, Liu Y . Rational design of ICD-inducing nanoparticles for cancer immunotherapy. Sci Adv. 2024; 10(6):eadk0716. PMC: 10849581. DOI: 10.1126/sciadv.adk0716. View

16.

Wang Y, Fletcher R, Yu J, Zhang L . Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018; 5(3):194-203. PMC: 6176216. DOI: 10.1016/j.gendis.2018.05.003. View

17.

Yasui H, Takai K, Yoshida R, HAYAISHI O . Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci U S A. 1986; 83(17):6622-6. PMC: 386556. DOI: 10.1073/pnas.83.17.6622. View

18.

Guo Y, Liu Y, Wu W, Ling D, Zhang Q, Zhao P . Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials. 2021; 276:121018. DOI: 10.1016/j.biomaterials.2021.121018. View

19.

Sun J, Wan Z, Chen Y, Xu J, Luo Z, Parise R . Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta Biomater. 2020; 106:289-300. PMC: 7183357. DOI: 10.1016/j.actbio.2020.01.039. View

20.

Shen F, Feng L, Zhu Y, Tao D, Xu J, Peng R . Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer. Biomaterials. 2020; 255:120190. DOI: 10.1016/j.biomaterials.2020.120190. View